Q3 2019 EPS Estimates for Becton Dickinson and Co Decreased by Analyst (BDX)

Becton Dickinson and Co (NYSE:BDX) – Analysts at Piper Jaffray Companies decreased their Q3 2019 earnings per share (EPS) estimates for Becton Dickinson and in a research note issued on Tuesday, November 6th. Piper Jaffray Companies analyst W. Quirk now forecasts that the medical instruments supplier will earn $3.07 per share for the quarter, down from their prior estimate of $3.29. Piper Jaffray Companies currently has a “Overweight” rating and a $250.00 target price on the stock. Piper Jaffray Companies also issued estimates for Becton Dickinson and’s Q1 2020 earnings at $3.17 EPS, Q2 2020 earnings at $3.42 EPS, Q3 2020 earnings at $3.67 EPS and Q4 2020 earnings at $3.68 EPS.

Becton Dickinson and (NYSE:BDX) last posted its earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $2.93. Becton Dickinson and had a net margin of 1.47% and a return on equity of 13.84%. The firm had revenue of $4.40 billion during the quarter, compared to the consensus estimate of $4.36 billion. During the same quarter last year, the firm earned $2.40 EPS. The firm’s revenue for the quarter was up 39.0% on a year-over-year basis.

Several other analysts also recently weighed in on BDX. KeyCorp reiterated a “buy” rating and issued a $264.00 target price on shares of Becton Dickinson and in a report on Friday, August 3rd. Royal Bank of Canada reiterated a “hold” rating and issued a $248.00 target price on shares of Becton Dickinson and in a report on Friday, August 3rd. Citigroup lifted their target price on shares of Becton Dickinson and from $274.00 to $283.00 and gave the company a “buy” rating in a report on Wednesday, August 8th. Wells Fargo & Co lifted their target price on shares of Becton Dickinson and from $275.00 to $290.00 and gave the company an “outperform” rating in a report on Thursday, September 6th. They noted that the move was a valuation call. Finally, Morgan Stanley lifted their target price on shares of Becton Dickinson and from $250.00 to $280.00 and gave the company an “equal weight” rating in a report on Thursday, October 4th. Five investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $254.07.

Becton Dickinson and stock opened at $243.26 on Thursday. Becton Dickinson and has a fifty-two week low of $209.91 and a fifty-two week high of $265.87. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.23 and a quick ratio of 0.81. The company has a market capitalization of $63.38 billion, a P/E ratio of 22.09, a P/E/G ratio of 1.46 and a beta of 1.19.

In other Becton Dickinson and news, EVP James C. Lim sold 5,189 shares of the firm’s stock in a transaction that occurred on Thursday, November 8th. The shares were sold at an average price of $242.36, for a total value of $1,257,606.04. Following the completion of the transaction, the executive vice president now owns 13,318 shares of the company’s stock, valued at approximately $3,227,750.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Timothy M. Ring sold 42,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 7th. The shares were sold at an average price of $237.07, for a total transaction of $9,956,940.00. Following the completion of the transaction, the director now directly owns 93,688 shares of the company’s stock, valued at approximately $22,210,614.16. The disclosure for this sale can be found here. Company insiders own 1.00% of the company’s stock.

A number of hedge funds have recently modified their holdings of the business. Acropolis Investment Management LLC purchased a new stake in shares of Becton Dickinson and during the 3rd quarter worth $101,000. Almanack Investment Partners LLC. acquired a new stake in Becton Dickinson and during the 2nd quarter worth $105,000. Truvestments Capital LLC acquired a new stake in Becton Dickinson and during the 3rd quarter worth $105,000. Bartlett & Co. LLC raised its stake in Becton Dickinson and by 2,900.0% during the 2nd quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock worth $108,000 after acquiring an additional 435 shares in the last quarter. Finally, Bridgeworth LLC acquired a new stake in Becton Dickinson and during the 2nd quarter worth $131,000. 92.60% of the stock is owned by institutional investors.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

See Also: Return on Investment (ROI) Defined, Explained

Earnings History and Estimates for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply